ArticleScientific reports2025
miR-361-5p contributes to the pathogenesis of Alzheimer's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. This study investigated the roles of HOMER1, ATAD1, and miR-361 in AD pathogenesis using microarray (GSE106241, GSE157239; n = 60) and RT-PCR (n = 100; 50 AD patients, 50 controls from Northwest Iran) analyses. Decreased expression of HOMER1 and ATAD1, key regulators of glutamatergic synapses, and miR-361, a potential regulator of both, was observed in AD brain tissue (GSE106241, categorized into seven Braak stages), suggesting a link between their dysregulation, impaired synaptic function, and increased neuroinflammation. However, blood-based RT-PCR showed no significant difference in HOMER1 or ATAD1. miR-361 was significantly lower in AD patients (adjusted p < 0.043). These findings, limited by sample size and lacking a formal power analysis, require further investigation to validate their potential as peripheral biomarkers for AD. Future studies with larger sample sizes are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.